Supplementary Figure 1 from HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation
christian young
View PDFchevron_right
Supplementary Figure 2 from HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation
christian young
View PDFchevron_right
Regulation of ERBB3/HER3 signaling in cancer
Zhiqiang An, Ningyan Zhang
Oncotarget, 2014
View PDFchevron_right
Activating HER3 mutations in breast cancer
Samar Alanazi
Oncotarget
View PDFchevron_right
A Central Role for HER3 in HER2Amplified Breast Cancer: Implications for Targeted Therapy
Thinh Pham
2008
View PDFchevron_right
Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
Anindita Chakrabarty
Proceedings of the National Academy of Sciences, 2012
View PDFchevron_right
HER-2 Signaling in Human Breast Cancer
Kathleen Ignatoski
Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways, 2011
View PDFchevron_right
Biologic and therapeutic role of HER2 in cancer
Elda Tagliabue
Oncogene, 2003
View PDFchevron_right
Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem
Cancer Drug Resistance
Cancer Drug Resistance, 2020
View PDFchevron_right
HER3 signaling and targeted therapy in cancer
Samar Alanazi
Oncology Reviews
View PDFchevron_right
Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2Positive Metastatic Breast Cancer
Jodi Weidler
PLOS One, 2012
View PDFchevron_right
ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
Zhiqiang An, Ningyan Zhang
Cancer medicine, 2012
View PDFchevron_right
HER3 and LINC00052 interplay promotes tumor growth in breast cancer
Ningyan Zhang
Oncotarget, 2016
View PDFchevron_right
Therapeutics , Targets , and Chemical Biology ErbB 3 Ablation Impairs PI 3 K / Akt-Dependent Mammary Tumorigenesis
Anindita Chakrabarty
2011
View PDFchevron_right
Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells
William Bornmann
Molecular Cancer Therapeutics, 2008
View PDFchevron_right
Expression of HER2 in Breast Cancer Promotes a Massive Reorganization of Gene Activity and Suggests a Role for Epigenetic Regulation
Michael McClelland
Journal of data mining in genomics & proteomics, 2012
View PDFchevron_right
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
Alexandra Leary
Clinical cancer research : an official journal of the American Association for Cancer Research, 2014
View PDFchevron_right
Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
Nicholas Lewin-koh
Clinical Cancer Research, 2009
View PDFchevron_right
HER3 Alterations in Cancer and Potential Clinical Implications
Samar Alanazi
Cancers
View PDFchevron_right
HER-2 in breast cancer—methods of detection, clinical significance and future prospects for treatment
Sarah Pinder
Critical Reviews in Oncology Hematology, 2002
View PDFchevron_right
HER2 Gene Amplification, HER2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
Ann Marie Martin
2008
View PDFchevron_right
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
Joaquín Arribas
Oncogene, 2011
View PDFchevron_right
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
Jaime Olmo Fernández
View PDFchevron_right
Uncoupling of PI3K from ErbB3 Impairs Mammary Gland Development but Does Not Impact on ErbB2-Induced Mammary Tumorigenesis
William Muller
Cancer Research, 2012
View PDFchevron_right
Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
Isabel Calvo
Breast Cancer Research, 2014
View PDFchevron_right
Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line
Johan Lennartsson
Biochemical and Biophysical Research Communications, 2008
View PDFchevron_right
ONCOLOGIA E PATOLOGIA SPERIMENTALE XXIX Ciclo DEVELOPMENT OF PRECLINICAL MODELS OF MAMMARY CARCINOGENESIS: FUNCTIONAL ROLE OF HER2 AND ITS ISOFORMS IN TUMOR PROGRESSION AND IN DRUG RESISTANCE
roberta Laranga
View PDFchevron_right
Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer
Patricia Elizalde
BMC Cancer, 2012
View PDFchevron_right
Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
Anna Bergamaschi
Science Signaling, 2014
View PDFchevron_right